M2RLAB, S.L.
Onglets principaux
À propos de votre organisation / profil
M2RLAB IS A BIOTECH COMPANY WHERE WE HAVE DEVELOPED A BREAKTHROUGH CELL THERAPY TO CURE ACUTE FIBROTIC DESEASES, AND ACUTE KIDNEY INJURY IS OUR FIRST TARGET.
WE DO OUR RESEARCH FROM TWO LAB FACILITIES LOCATED AT TOP PUBLIC RESEARCH INSTITUTES IN BARCELONA AND MADRID. AND WE ALSO HAVE OPENED A CENTRALIZED PRODUCTION FACILITY FOR OUR CELL THERAPY TO SERVE A WIDE GEOGRAPHICAL AREA AS PART AS OUR CLINICAL PROGRAM TO TREAT AKI. WE ARE PRESENTING A PHASE II CLINICAL TRIAL FOR 120 PATIENTS IN Q1 2024.
OUR TECHNOLOGY IS SIMPLE TO MANUFACTURE, SCALABLE AND IS PROTECTED BY PATENTS IN THE EU, USA, JAPAN AND 5 OTHER MARKETS. IN ADDITION TO KIDNEY INJURY WE HAVE PRECLINICAL APPLICATIONS FOR ARDS, LUPUS NEPHRITIS AND TENDON INJURY.
YOU CAN CHECK MORE AT WWW.M2RLAB.COM
Activités récentes
M2RLAB, S.L. est désormais membre de la communauté EIC ACCESS+.
M2RLAB, S.L. a obtenu le label FUNDACIÓN PARA EL CONOCIMIENTO MADRI+D.
M2RLAB, S.L. a rejoint le réseau de WOMEN ANGELS FOR STEAM.
M2RLAB, S.L. a rejoint le réseau de Supernova Invest.
La dataroom a été mise à jour.
M2RLAB, S.L. est désormais membre de la communauté EEN2EIC - Seal of Excellence.
La dataroom a été mise à jour.
Pablo García de la Riva Mestre a rejoint M2RLAB, S.L..
Pablo Garcia de la Riva a rejoint M2RLAB, S.L..